
Opinion|Videos|January 16, 2026
The Role of Elacestrant in ER+/HER2– Advanced Breast Cancer Harboring ESR1 Mutations
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.
Advertisement
Episodes in this series

Hope S. Rugo, MD, and Seth Wander, MD, PhD, explore the clinical role of elacestrant (Orserdu) in estrogen receptor/HER2-negative advanced breast cancer with ESR1 mutations following the agent’s January 2023 FDA approval for use in patients with disease progression following at least 1 line of endocrine therapy. They discuss how this oral SERD addresses endocrine resistance and fits into current treatment algorithms. Rugo and Wander place elacestrant’s activity in context of evolving post-CDK4/6 inhibitor therapeutic options.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

